Hourglass Capital LLC lessened its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 22.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 137,630 shares of the pharmaceutical company’s stock after selling 39,100 shares during the quarter. Hourglass Capital LLC’s holdings in GlaxoSmithKline were worth $4,882,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also modified their holdings of GSK. Pinnacle Financial Partners Inc. grew its position in shares of GlaxoSmithKline by 24.1% during the fourth quarter. Pinnacle Financial Partners Inc. now owns 15,562 shares of the pharmaceutical company’s stock worth $552,000 after acquiring an additional 3,025 shares during the last quarter. Sei Investments Co. grew its position in shares of GlaxoSmithKline by 71.6% during the fourth quarter. Sei Investments Co. now owns 577,621 shares of the pharmaceutical company’s stock worth $20,488,000 after acquiring an additional 241,059 shares during the last quarter. Rational Advisors LLC grew its position in shares of GlaxoSmithKline by 328.1% during the fourth quarter. Rational Advisors LLC now owns 65,240 shares of the pharmaceutical company’s stock worth $2,314,000 after acquiring an additional 50,000 shares during the last quarter. Keeler Thomas Management LLC acquired a new stake in shares of GlaxoSmithKline during the fourth quarter worth $911,000. Finally, Krueger & Catalano Capital Partners LLC acquired a new stake in shares of GlaxoSmithKline during the fourth quarter worth $324,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.
GlaxoSmithKline plc (NYSE GSK) traded down $0.12 during trading on Tuesday, reaching $37.58. The company had a trading volume of 2,466,716 shares, compared to its average volume of 5,171,428. The stock has a market cap of $90,720.00, a PE ratio of 31.06, a PEG ratio of 2.37 and a beta of 0.98. GlaxoSmithKline plc has a 1 year low of $34.52 and a 1 year high of $44.53. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.03. The firm had revenue of $10.14 billion during the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. equities research analysts predict that GlaxoSmithKline plc will post 2.85 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be issued a $0.633 dividend. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 annualized dividend and a yield of 6.74%. GlaxoSmithKline’s payout ratio is 168.60%.
Several equities research analysts recently weighed in on GSK shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, October 24th. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Bank of America downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. TheStreet raised GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Finally, Investec downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.97.
WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2018/02/20/glaxosmithkline-plc-gsk-shares-sold-by-hourglass-capital-llc.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.